论文部分内容阅读
目的 :探讨原发性肝细胞癌合并癌性腹水的综合治疗方案。方法 :将 5 6例肝癌合并腹水患者随机分为两组 :腹腔化疗 ,加生物治疗配合肝动脉化疗栓塞患者 2 8例为观察组 ;单纯肝动脉化疗栓塞患者 2 8例为对照组。结果 :观察组首次治疗 1月后控制腹水的有效率和 1年、2年的生存率分别为 85 .7% (2 4 / 2 8)、5 7.1% (16 / 2 8)、2 8.6 % (8/ 2 8)、而对照组分别为 5 7.1% (16 / 2 8)、2 8.6 % (8/ 2 8)、7.1% (2 / 2 8) ,两组比较有显著性差异 (χ2 值分别为 5 .6 0、4 .6 7、4 .38,P <0 .0 5 )。结论 :腹腔穿刺放净腹水 ,卡铂针剂腹腔内注射 ,补充人血白蛋白 ,加生物治疗配合肝动脉化疗栓塞是肝癌合并腹水有效的综合治疗方案。
Objective: To investigate the comprehensive treatment of primary hepatocellular carcinoma with cancerous ascites. Methods: 56 cases of hepatocellular carcinoma with ascites were randomly divided into two groups: intraperitoneal chemotherapy plus biotherapy with hepatic arterial chemoembolization in 28 cases as observation group, and only hepatic arterial chemoembolization in 28 cases as control group. Results: The effective rate of ascites and the 1-year and 2-year survival rate of the observation group after first treatment for one month were 85.7% (2 4/2 8), 5 7.1% (16/2 8), 2 8.6% (8/28), while the control group were 51.1% (16/28), 28.6% (8/28) and 7.1% (2/8) respectively, there was significant difference between the two groups (χ2 Respectively, the value of 5.60,4.67,4.38, P <0. 05). Conclusions: Intraperitoneal puncture ascites, carboplatin injection intraperitoneal injection, supplementation of human serum albumin, and biotherapy combined with transcatheter arterial chemoembolization is an effective comprehensive treatment of liver cancer combined with ascites.